Table 1.
Descriptive statistics of the study populations (n = 16,335 total participants)*
| RS‐I (n = 7,983) | RS‐II (n = 3,011) | RS‐III (n = 3,932) | CHECK study (n = 1,002) | PROOF study (n = 407) | |
|---|---|---|---|---|---|
| No. of participants with genetic data available (female sex, %) | 6,291 (60.1) | 2,157 (54.4) | 3,048 (56.3) | 908 (79) | 328 (100) |
| Baseline age, range/mean ± SD years | 55–99/69.5 ± 9.2 | 55–95/64.8 ± 8.0 | 45–97/57.1 ± 6.9 | 45.1–65.1/55.9 ± 5.2 | 50.2–61.9/55.8 ± 3.2 |
| Baseline BMI, range/mean ± SD kg/m2 | 14.2–50.7/26.3 ± 3.7 | 16.7–50.6/27.2 ± 4.0 | 12.6–56.9/27.7 ± 4.6 | 18.1–40.1/26.2 ± 4.1 | 26.1–48.6/31.9 ± 4.1 |
| Hip PRS (original), range/mean ± SD† | 1.33–5.07/2.52 ± 0.29 | 1.59–4.73/2.51 ± 0.3 | 1.57–4.86/2.52 ± 0.29 | 1.74–4.77/2.51 ± 0.29 | 1.78–3.4/2.5 ± 0.27 |
| Hip PRS (without RS), range/mean ± SD‡ | 1.33–5.09/2.54 ± 0.30 | 1.6–4.76/2.54 ± 0.3 | 1.6–4.89/2.54 ± 0.3 | 1.76–4.8/2.54 ± 0.29 | 1.8–3.44/2.53 ± 0.27 |
| Knee PRS (original), range/mean ± SD† | 0.56–1.96/1.26 ± 0.17 | 0.8–1.81/1.27 ± 0.16 | 0.68–1.86/1.26 ± 0.16 | 0.65–1.68/1.25 ± 0.16 | 0.84–1.68/1.26 ± 0.16 |
| Knee PRS (without RS), range/mean ± SD‡ | 0.55–1.94/1.25 ± 0.17 | 0.8–1.8/1.26 ± 0.16 | 0.68–1.85/1.26 ± 0.16 | 0.64–1.67/1.24 ± 0.16 | 0.83–1.67/1.25 ± 0.16 |
| Radiographic OA, % | |||||
| Prevalent hip | 9.7 | 5.5 | 2.3 | 6.0 | – |
| Incident hip | 7.8 | 11.6 | 5.7 | 56.9 | – |
| Prevalent knee | 19.5 | 14.2 | 8.9 | 6.6 | 9.5 |
| Incident knee | 14.9 | 14.1 | 7.5 | 71.7 | 16.9 |
| Clinical OA, % | |||||
| Prevalent hip | 7.8 | 5.4 | 2.0 | – | – |
| Incident hip | 5.8 | 6.5 | 1.6 | 28.4 | – |
| Prevalent knee | 20.7 | 22.2 | 14.6 | – | – |
| Incident knee | 18.1 | 9.9 | 5.5 | 49.6 | 10.7 |
| TJR, % | |||||
| Prevalent hip | 3.3 | 2.1 | 1.0 | – | – |
| Incident hip | 3.1 | 3.9 | 0.8 | 10.4 | – |
| Prevalent knee | 0.7 | 1.0 | 0.6 | – | – |
| Incident knee | 1.8 | 3.6 | 1.2 | 5.8 | – |
*
RS‐I = Rotterdam Study cohort I; CHECK = Cohort Hip and Cohort Knee; PROOF = Prevention of Knee Osteoarthritis in Overweight Females; BMI = body mass index; TJR = total joint replacement.
†
Polygenic risk scores (PRS) based on the initially reported effect sizes for osteoarthritis (OA) in 826,690 participants across 13 cohorts worldwide in 10 different OA phenotypes by the Genetics of OA (GO) consortium meta‐analysis.
‡
PRS based on the secondary reported effect sizes for only hip OA and knee OA after excluding the Rotterdam Study from the meta‐analysis by the GO consortium.